Skip to main content

Advertisement

SpringerLink
Log in

Reduced risk of bacterial infection in multiple myeloma patients with VAD regimen without intermittent high-dose dexamethasone

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Vincristine-adriamycin-dexamethasone (VAD) regimen with intermittent high-dose dexamethasone (HD) has been used as primary chemotherapy for multiple myeloma (MM) patients who are candidates for high-dose therapy or present with renal failure. However, dexamethasone increases the risk of infection in MM patients. We retrospectively evaluated treatment efficacy and infectious events in MM patients undergoing VAD with or without HD. Seventy-seven consecutive patients who received VAD without HD (n = 37) or VAD-HD (n = 40) at our institution were assessed. Characteristics of patients and VAD regimens were retrospectively analyzed to detect correlations with the incidence of infections. During 218 VAD cycles, 48 infectious episodes were documented in 39 patients. Of these, 32 episodes in 26 patients were severe (grade ≥ 3). By analyzing each patient, VAD-HD was associated with risk of all-grade and severe bacterial infection, while International Staging System stage ≥ 2 was independently correlated with severe bacterial infection. Response rates after two cycles were comparable between the 2 VAD regimens. In conclusion, risk of infection is lower in VAD without HD than in VAD-HD, and the clinical response is equivalent. VAD-HD should thus be avoided for MM patients with high risk of infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353–6.

    Article  CAS  PubMed  Google Scholar 

  2. Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol. 1999;105:127–30.

    Article  CAS  PubMed  Google Scholar 

  3. Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 1989;2:882–5.

    Article  CAS  PubMed  Google Scholar 

  4. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86–9.

    Article  CAS  PubMed  Google Scholar 

  5. Mills KH, Cawley JC. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br J Haematol. 1983;53:271–5.

    Article  CAS  PubMed  Google Scholar 

  6. Pilarski LM, Andrews EJ, Serra HM, Ruether BA, Mant MJ. Comparative analysis of immunodeficiency in patients with monoclonal gammopathy of undetermined significance and patients with untreated multiple myeloma. Scand J Immunol. 1989;29:217–28.

    Article  CAS  PubMed  Google Scholar 

  7. Jacobson DR, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Semin Oncol. 1986;13:282–90.

    CAS  PubMed  Google Scholar 

  8. Wearne A, Joshua DE, Kronenberg H. Light chain isotype associated suppression of surface immunoglobulin expression on peripheral blood lymphocytes in myeloma during plateau phase. Br J Haematol. 1984;58:483–9.

    Article  CAS  PubMed  Google Scholar 

  9. Hargreaves RM, Lea JR, Griffiths H, Faux JA, Holt JM, Reid C, et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol. 1995;48:260–6.

    Article  CAS  PubMed  Google Scholar 

  10. Bladé J. Management of renal, hematologic, and infectious complications. In: Malpas JS, Bergsagel DE, Kyel RA, Anderson KC, editors. Myeloma: biology and management. 3rd ed. Philadelphia: Saunders, Elsevier Inc.; 2004. p. 261–7.

  11. Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer. 1995;71:326–30.

    CAS  PubMed  Google Scholar 

  12. Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Hullin C, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial. ASCO Annual Meeting. 2008 (abstract 8505).

  13. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35–9.

    Article  CAS  PubMed  Google Scholar 

  14. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102:1115–23.

    Article  PubMed  Google Scholar 

  15. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.

    Article  CAS  PubMed  Google Scholar 

  16. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80:887–90.

    CAS  PubMed  Google Scholar 

  17. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transpl. 2004;34:485–90.

    Article  CAS  Google Scholar 

  18. Perri RT, Hebbel RP, Oken MM. Influence of treatment and response status on infection risk in multiple myeloma. Am J Med. 1981;71:935–40.

    Article  CAS  PubMed  Google Scholar 

  19. Cesana C, Nosari AM, Klersy C, Miqueleiz S, Rossi V, Ferrando P, et al. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. Haematologica. 2003;88:1022–8.

    PubMed  Google Scholar 

  20. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.

    Article  PubMed  Google Scholar 

  21. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest. 1989;84:2008–11.

    Article  CAS  PubMed  Google Scholar 

  22. Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med. 1996;100:624–8.

    Article  CAS  PubMed  Google Scholar 

  23. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary complications of HIV infection study group. N Engl J Med. 1995;333:845–51.

    Article  CAS  PubMed  Google Scholar 

  24. Kumar SK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transpl. 2008;41:1013–9.

    Article  CAS  Google Scholar 

  25. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001;12:991–5.

    Article  CAS  PubMed  Google Scholar 

  26. Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91:929–34.

    CAS  PubMed  Google Scholar 

  27. Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B, et al. Thalidomide–dexamethasone compared with melphalan–prednisolone in elderly patients with multiple myeloma. Blood. 2009;113:3435–42.

    Article  CAS  PubMed  Google Scholar 

  28. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, National Hospital Organization Nishigunma National Hospital, 2854 Kanai, Shibukawa, Gunma, 377-8511, Japan

    Atsushi Isoda, Morio Matsumoto, Hirotaka Nakahashi, Momoko Mawatari & Morio Sawamura

  2. Department of Pharmacy, National Hospital Organization Nishigunma National Hospital, Shibukawa, Gunma, Japan

    Akihiro Manaka

Authors
  1. Atsushi Isoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morio Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hirotaka Nakahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Momoko Mawatari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akihiro Manaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Morio Sawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atsushi Isoda.

About this article

Cite this article

Isoda, A., Matsumoto, M., Nakahashi, H. et al. Reduced risk of bacterial infection in multiple myeloma patients with VAD regimen without intermittent high-dose dexamethasone. Int J Hematol 93, 59–65 (2011). https://doi.org/10.1007/s12185-010-0735-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-010-0735-1

Keywords

Search

Navigation